, Volume 84, Issue 12, pp 830-832

Occurrence of multiple myeloma 13 years after Hodgkin’s disease: chance or consequence?

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Dear Editor,

Chemo- (CTx) and radiotherapy (RTx), either given alone or combined, have considerably improved cure rates of various malignancies, including Hodgkin’s disease (HD). Data from the German HD Study Group have reported a 5-year overall survival for advanced disease with intensified BEACOPP, standard BEACOPP, and COPP–ABVD ranging between 80 and 90% [3]. Nevertheless, despite significant improvement in cancer prognosis due to novel CTx combinations, targeted therapies (including antibodies) and intensive strategies (using autologous and allogeneic stem cell transplantation), treatment-related complications, the most serious being secondary malignancies, may occur. These secondary malignancies mostly comprise of acute leukemias, especially acute myeloid leukemias (AML) and myelodysplastic syndromes (MDS), but also non-Hodgkin’s lymphomas (NHL) and solid tumors (ST) [8].

Here we report on the occurrence of a multiple myeloma (MM) in a patient (pt) who had successfully been treated